Cisplatin's Effect on Ovarian Cancer Cells and p53 Status
Author Information
Author(s): P De Feudis, D Debernardis, P Beccaglial, M Valenti, E Graniela Sir6l, D Arzani, S Stanzione, S Parodi, M D'Incalci, P Russo, M Broggini
Primary Institution: Istituto di Ricerche Farmacologiche 'Mario Negri', Milan, Italy; Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy
Hypothesis
Does the presence of wild-type p53 influence the cytotoxicity of cisplatin in human ovarian cancer cell lines?
Conclusion
The presence of wild-type p53 does not determine the cytotoxicity induced by cisplatin in human ovarian cancer cell lines.
Supporting Evidence
- Nine ovarian cancer cell lines were used to evaluate the effects of cisplatin.
- No differences in cytotoxicity were found between cells with wild-type and mutated p53.
- DDP treatment increased p53 levels in some cell lines, but this did not correlate with cytotoxicity.
- Apoptosis was observed but was generally low across all cell lines.
Takeaway
This study found that whether ovarian cancer cells have normal or mutated p53 doesn't change how well cisplatin works to kill them.
Methodology
Nine human ovarian cancer cell lines were treated with cisplatin, and the cytotoxicity was evaluated using the MTT test and analysis of p53 and downstream gene levels.
Limitations
The study was conducted in vitro, which may not fully represent the conditions in actual tumors.
Want to read the original?
Access the complete publication on the publisher's website